Our Technology


The Company’s vaccine for COVID19 is based on a ONCoat™ Synthetic Engineered adenovirus vector (Ad5), protected from immune neutralization, and expressing the SARS-CoV-2 spike protein


ONCoat™ Synthetic Vector Vaccine

E1 & E3 deleted replication deficient Ad5 (Human) Adenovirus vector encoding SARS-CoV-2 spike protein

  • Protection from adenovirus vector neutralization
  • Booster shots are not affected by neutralizing antibodies produced from prior immunizations
  • Improved antigen expression
  • Encapsulation improves immunity
  • Improved vector stability for storage and distribution

ONCoat™ encapsulated SARS-CoV-2 spike protein

  • Highest encapsulation capacity reported in literature that improves efficacy
  • Easy surface functionalization to increase tissue retention and enhance phagocytic uptake
  • Flexible adjustment of nanoparticle size and physical properties to affect the release kinetics

ONCoat™ encapsulated viral RNA

  • Effective delivery of viral RNA delivery into cells
  • Adjustable slow release over time
  • Low cost and easy scalability
  • Improved RNA stability

ONCoat™ encapsulated inactivated SARS-CoV-19

  • Adjustable slow release over time eliminates the need for booster shots
  • Improved efficacy
  • Improves the stability of the virus storage and distribution

ONCoat™ encapsulated attenuated SARS-CoV-19

  • Most effective to generate immune response but higher chance of clearance and neutralization
  • Coating prevents immediate clearance and neutralization and slowly release virus
  • Additional phagocyte targeting improves efficacy
  • Higher efficacy with lower dose reducing side effects


Designer Encapsulated Vector Assembly

Get In Touch

6650 Lusk Blvd.
Suite B105
San Diego CA 92121


Scroll to Top